Foreign media: The Trump administration is considering strict restrictions on Chinese pharmaceuticals, which could disrupt the U.S. pharmaceutical industry and affect the supply of drugs ranging from generic medicines to cutting-edge treatments. The core issue is a proposed executive order that may cut off the supply of experimental drugs developed in China.
Large pharmaceutical companies have been purchasing drugs developed in China for treating diseases such as cancer, obesity, heart disease, and Crohn's disease. This proposal has sparked intense lobbying from both sides.
One side consists of investors and executives closely associated with Trump, including Peter Thiel, Google co-founder Sergey Brin, the Koch family, and the investment company of Trump's son-in-law Jared Kushner, who advocate taking a tough stance against China to address the "existential threat" China poses to the U.S. biotechnology industry. The other side consists of the world's largest pharmaceutical companies, such as Pfizer and AstraZeneca, which purchase low-cost experimental drugs from China and oppose the restrictions.
Original article: www.toutiao.com/article/1842889168374788/
Statement: The article represents the views of the author.